Although lamin-deficient cancer cells had lower PD-L1 and stemness markers (Figures 1C, 4B), the sorafenib did not alter PD-L1 and CD133 levels on cancer cells with or without lamin knockdown (Figures 5F, G). This evidence concerns the gene PROM1 and cancer.